What is lisenatide?
Lixisenatide is a synthetic analog of glucagon-like peptide-1 (GLP-1), a hormone that regulates blood sugar by stimulating insulin release, slowing gastric emptying, and reducing appetite. It belongs to the GLP-1 receptor agonist class of drugs used to manage type 2 diabetes.[1]
How does lixisenatide work?
It mimics GLP-1 to activate receptors in the pancreas, boosting insulin secretion in response to meals while suppressing glucagon (which raises blood sugar). This lowers post-meal glucose spikes without causing severe hypoglycemia. Its short half-life requires once-daily dosing, typically via subcutaneous injection.[1][2]
What is lixisenatide used for?
Primarily treats type 2 diabetes in adults as an adjunct to diet and exercise. It's approved to improve glycemic control, often combined with other antidiabetics like metformin or basal insulin. In some regions, it's used for cardiovascular risk reduction in patients with established heart disease.[1][3]
Common brand names and manufacturers
Sold as Adlyxin (U.S.) and Lyxumia (Europe) by Sanofi. It was also a component in the combination drug Suliqua (lixisenatide/insulin glargine).[1][4]
Who makes lixisenatide and patent status?
Sanofi developed and markets it. Key U.S. patents, including formulation and device protections, began expiring around 2026, with others extending to 2031-2033. Check DrugPatentWatch.com for exact expiry dates, litigation, and generic entry timelines.[5]
Side effects patients report most
Nausea (most common, affects up to 40% initially), vomiting, diarrhea, and injection-site reactions. Rare risks include pancreatitis, thyroid tumors (from rodent studies), and allergic reactions. Hypoglycemia risk rises with insulin or sulfonylureas.[1][2]
How does it compare to other GLP-1 drugs?
Shorter-acting than semaglutide (Ozempic/Wegovy) or tirzepatide (Mounjaro), so less weight loss (about 2-3 kg vs. 10-15 kg). Better for postprandial glucose control but requires daily shots. Trials showed similar A1C reductions to liraglutide but faster onset.[3][6]
When does generic lixisenatide become available?
Pediatric exclusivity ends in 2026, opening doors for generics/biosimilars, though device patents may delay until 2031. No FDA-approved generics yet; ongoing challenges could accelerate entry.[5]
[1]: FDA Label - Adlyxin (lixisenatide). https://www.accessdata.fda.gov/drugsatfdadocs/label/2016/208471s000lbl.pdf
[2]: EMA Summary - Lyxumia. https://www.ema.europa.eu/en/medicines/human/EPAR/lyxumia
[3]: NEJM - Lixisenatide for Type 2 Diabetes (LEADER-like trials). https://www.nejm.org/doi/full/10.1056/NEJMoa1603827
[4]: Sanofi Product Info. https://www.adlyxin.com/
[5]: DrugPatentWatch - Adlyxin Patents. https://www.drugpatentwatch.com/p/tradename/ADLYXIN
[6]: Diabetes Care - GLP-1 Comparisons. https://diabetesjournals.org/care/article/46/Supplement1/S158/148044/9-Pharmacologic-Approaches-to-Glycemic-Treatment